Small Cell Lung Cancer (SCLC) is a very aggressive form of lung cancer with a high unmet need. Until recently chemotherapy was the only treatment option. The addition of immune checkpoint inhibitors (ICI) to chemotherapy did show minimal increases in OS and has become the new standard of care for 1st-line treatment. Future development includes ICI combinations and novel chemotherapy agents, but there is a great need for truly innovative therapies.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Small Cell Lung Cancer to help guide strategic and tactical commercial development decisions for market participants.